MedTrace Logo

Comparative Atorvastatin Pleiotropic Effects

NCT00163202 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 330

Last updated 2021-02-18

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.

Conditions

Interventions

PROCEDURE

Blood samples

DRUG

Atorvastatin

Sponsors & Collaborators

  • MDS Pharma Services

    collaborator INDUSTRY

  • Bio-Inova Life Sciences International

    collaborator OTHER

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Completion
2005-08-31

Countries

  • Canada
  • Czechia
  • France
  • Poland
  • Romania
  • Russia
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00163202 on ClinicalTrials.gov